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The completion of the draft sequence of the human
genome1 2 has raised public awareness of “genomics”
and of the ways in which the emerging technologies of
the genomics “revolution” will have direct applications
to patient care.3 DNA microarrays, or biochips, are
prominent among these new technologies. The past
five years have seen a dramatic rise in the use of DNA
microarrays for biomedical research, in some cases
with immediate applicability to clinical practice. The
uses of microarrays for gene expression profiling,
genotyping, mutation detection, and gene discovery
are leading to remarkable insights into the function of
thousands of genes previously known only by their
gene sequence. This review discusses ways in which
microarrays have started to affect clinical practice and
research and how this role will develop in the next five
to 10 years.
Methods
The data for this review reflect my personal views from
10 years of research in molecular medicine and five
years on DNA microarrays. My views have developed
over this period from discussions with colleagues in my
own laboratory and at basic science and biotechnology
meetings and from regular reading of Nature Genetics,
Nature, Science, and other journals.
What are DNA microarrays?
For the past 25 years, the standard techniques used to
detect specific sequences of DNA or RNA in the labo›
ratory have depended on the use of a DNA probe
labelled with, for example, a radioactive isotope or a
fluorescent tag. The probe is complementary in
sequence to the fragment of DNA or RNA to be
detected, and so it hybridises (or sticks) selectively, by
Watson›Crick base pairing, to the correct fragment of
DNA or RNA if that fragment is present in the test
sample.
The principle of DNA microarrays is that
technological advances have made it possible to minia›
turise this DNA probe detection method. Instead of
detecting and studying one gene at a time, microarrays
allow thousands or tens of thousands of specific DNA
or RNA sequences to be detected simultaneously on a
small glass or silica slide only 1›2 cm square. Although
the principles of specific DNA and RNA detection have
remained unchanged, the greatly increased scale on
which this can be achieved with DNA microarrays has
made it possible to tackle qualitatively different
questions in biology and medicine.
Microarray manufacture
Two main methods are used to make microarrays. In
the first, DNA is spotted onto a glass slide (fig 1); in the
second, oligonucleotides of 15›30 nucleic acid base
pairs are synthesised on to a silica slide by a process
known as photolithography (fig 2).
The technology for producing spotted microarrays
(fig 1) is widely accessible, and spotted arrays are now
produced in scores of biomedical research institutions.
Production and use of custom arrays are now within
the grasp of any molecular biology laboratory, and,
once the DNA has been prepared, the costs are low.
The disadvantage of this technique is that consistency
of spotting and reliable annotation of the DNA on the
microarray are hard to achieve.
The photolithography technique, initially bor›
rowed from the semiconductor industry, is limited to a
small number of manufacturers, of whom the best
known is Affymetrix, a California based biotechnology
firm that has cornered a large share of the microarray
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market. The very high spot (or “feature”) density pos›
sible with photolithography (fig 2) means that the
expression of up to 15 000 genes can be measured on
a single slide (the signal for each being derived from
about 30 spots). Although these commercial arrays
have high unit costs, the consistency between arrays is
assured by the production process, and microarrays
representing most of the genes in the human genome
and a range of other genomes can be bought ready for
use without the need for development by the user.
Major applications of microarrays
The major applications of microarrays fall into three
groups:
Gene expression profiling—RNA extracted from a
complex sample (such as body tissues or fluids or bac›
terial isolates) is applied to the microarray. The result
reveals the level of expression of tens of thousands of
genes, effectively all the genes in the genome, in that
complex sample. This result is known as a gene expres›
sion “profile” or “signature.”
Genotyping—Genomic DNA, extracted from an indi›
vidual’s blood or saliva, is amplified by the polymerase
chain reaction and applied to the microarray. The geno›
type for hundreds or thousands of genetic markers
across the genome can be determined in a single
hybridisation. This approach has considerable potential
in risk assessment, both in research and clinical practice.
DNA sequencing—DNA extracted from an individu›
al’s blood is amplified and applied to specific
“re›sequencing” microarrays. Thousands of base pairs
of DNA can be screened on a single microarray for
mutations in specific genes whose normal sequence is
already known. This greatly increases the scope for
precise molecular diagnosis in single gene and geneti›
cally complex diseases.
Expression profiling in clinical practice
The ability to measure the expression level of
thousands of genes in any tissue sample allows explo›
ration of gene function on a scale previously
impossible. Through global analysis of gene expres›
sion, the function of genes previously identified only by
their DNA sequence is now being discovered almost as
a matter of routine. The identification of new metabolic
pathways and pathogenetic mechanisms, new indica›
tors of disease prognosis, and new drug targets are
likely to be realised in several diseases in the next three
to five years and will start to enter clinical practice with
new treatment strategies within this time frame.
For individual patients, more precise diagnosis and
risk assessment based on expression profiles are
already achievable for certain conditions, leading to
more accurate determination of prognosis and more
individually tailored treatment. Oncology has taken the
lead in this area, although it is by no means the only
discipline to have realised the power of the technology.
Expression profiles in acute leukaemia, B cell
lymphoma, melanoma, and breast cancer have led to
new methods for disease staging and classification,
based on knowledge of the expressed genes in
individual tumours or cell populations.
Oncology
An example of this diagnostic approach is in acute leu›
kaemia, in which expression profiles of 6817 genes were
used to distinguish between acute lymphoid leukaemia
and acute myeloid leukaemia (fig 3). Independent of any
histological or histochemical diagnosis, the results
correctly classified 36 out of 38 “unknown” leukaemia
samples derived from either bone marrow or peripheral
blood.5 The remaining two samples could not be
assigned to either acute lymphoid or acute myeloid leu›
kaemia. However, the technique successfully divided
acute lymphoid leukaemia into T cell derived or B cell
derived leukaemia and raised new and intriguing
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Fig 1 Gene expression analysis in two tissue samples using spotted
DNA microarray. RNA extracted from samples 1 and 2 is labelled
with red or green fluorescent dyes. The dye labelled RNA populations
are mixed and hybridised to the microarray, on which has been
spotted cDNA from thousands of genes, each spot representing one
gene. The RNA from each sample hybridises to each spot in
proportion to the level of expression of that gene in the sample. After
hybridisation, the red and green fluorescent signal from each spot is
determined, and the ratio of red to green reflects the relative
expression of each gene in the two samples. For example, the gene
TEP1 is shown to be expressed at a higher level in sample 2 than in
sample 1. (Adapted with permission from Brown and Botstein4)
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Fig 2 Gene expression analysis using oligonucleotide microarray. Up
to half a million distinct oligonucleotides are synthesised on the
microarray by photolithography and act as probes in individual
“features” on the microarray surface. About 30 distinct
oligonucleotides, printed as individual features, represent the partial
sequence of one gene. Fluorescent labelled cDNA derived from a
single test sample is hybridised to the microarray, allowing the
expression level of up to 15 000 genes to be measured in the test
sample. (Illustration courtesy of Affymetrix, Santa Clara, CA, USA)
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insights into the role of the 50 most predictive genes in
disease pathogenesis.
A limitation of this study was that the results did
not allow new prognostic groups to be defined. This
was not the case for a similar study of diffuse large B
cell lymphoma.6 This condition is the commonest sub›
type of non›Hodgkin’s lymphoma and is notoriously
difficult to classify prognostically on morphological or
clinical grounds. It is therefore of considerable clinical
relevance that the gene expression analysis defined
new prognostic subgroups in diffuse large B cell
lymphoma, one with five year survival of 80% and one
with 40% survival (fig 4).
Similar studies have been made of metastatic and
non›metastatic melanoma,7 8 breast cancer,9 and colo›
rectal cancer.10 It seems likely that major new insights
will be derived for a wide range of cancers, leading to the
prospect of better targeted treatment and, in the longer
term, new treatments based on improved understanding
of the molecular pathogenesis of these diseases.
Infectious disease
Microarrays that detect gene sequences in the
genomes of Mycobacterium tuberculosis, HIV, and other
pathogens have been developed11 12 with the aim of
providing a diagnostic tool that detects expression of
antibiotic resistance genes or specifies viral subtypes. A
major advantage is that these tests can be undertaken
rapidly (in less than 24 hours) without the need for
bacterial or viral cultures. If such tests are brought into
clinical practice they will lead to earlier, more targeted
treatment based on antibiotic or antiviral sensitivities
C-myb(U22376)
Proteasome iota (X59417)
MB-1 (U05259)
Cyclin D3 (M92287)
Myosin light chain (M31211)
RbAp48 (X74262)
SNF2 (D26156)
HkrT-1 (S50223)
E2A (M31523)
Inducible protein (L47738)
Dynein light chain (U32944)
Topoisomerase II b  (Z15115)
IRF2 (X15949)
TFIIEb  (X63469)
Acyl-Coenzyme A dehydrogenase (M91432)
SNF2 (U29175)
(Ca2+)-ATPase (Z69881)
SRP9 (U20998)
MCM3 (D38073)
Deoxyphypusine synthase (U26266)
Op 18 (M31303)
Rabaptin-5 (Y08612)
Heterochromatin protein p25 (U35451)
IL-7 receptor (M29696)
Adenosine deaminase (M13792)
AML
-3 -2.5 -2 -1.5 -1 -0.5 0
Normalised expression
0.5 1 1.5 2 2.5 3
Low High
ALL
Fumarylacetoacetate (M55150)
Zyxin (X95735)
LTC4 synthase (U50136)
LYN (M16038)
Hox A9 (U82759)
CD33 (M23197)
Adipsin (M84526)
Leptin receptor (Y12670)
Cystatin C (M27891)
Proteoglycan 1 (X17042)
IL-8 precursor (Y00787)
Azurocidin (M96326)
p62 (U46751)
CyP3 (M80254)
MCL1 (L08254)
ATPase (M62762)
IL-8 (M28130)
Cathepsin D (M63138)
Lectin (M57710)
MAD-3 (M69043)
CD11c (M81695)
Ebp72 (X85116)
Lysozyme (M19045)
Properdin (M83652)
Catalase (X04085)
Fig 3 Genes distinguishing acute lymphoid leukaemia (ALL) from acute myeloid leukaemia (AML). The figure shows the 50 genes with the
greatest distinction between ALL and AML, the top panel showing genes more highly expressed in ALL and the bottom panel showing genes
more highly expressed in AML. Each row corresponds to a gene, with the columns corresponding to expression levels of these genes in
different patient samples. Expression levels greater than the mean are red, and those below the mean are blue. The scale indicates standard
deviations above or below the mean. (Adapted with permission from Golub et al5)
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and will be particularly valuable for organisms such as
M tuberculosis and HIV, for which sensitivity profiles can
presently be determined only after lengthy analysis by
other methods.
Microarrays for genotyping and
re›sequencing
The human genome sequencing projects have, over
the past two years, provided more than two million
single nucleotide polymorphisms (SNPs) as genetic
markers.2 13 These resources, coupled with improved
methods for genetic analysis, mean that systematic
identification of the genetic determinants of common,
genetically complex disorders is now being realised.14
As relevant genes are identified, the mutations and
polymorphisms that underlie susceptibility to a range
of common diseases will become direct predictors of
susceptibility. Likely examples include diabetes, hyper›
tension, coronary heart disease, asthma, inflammatory
bowel disease, cancer susceptibility, and susceptibility
to adverse and favourable drug responsiveness.
Genotyping arrays, or “SNP chips,” offer one
option for use of these new genetic markers of disease
and drug responsiveness. These arrays, capable of
genotyping up to 2000 polymorphisms in a single
hybridisation,15 16 will allow the construction of an indi›
vidual’s “genetic fingerprint,” that can be related to his
or her risk of developing single gene disorders or more
common complex diseases.
Clinical pharmacology
The approach is already being applied in clinical phar›
macology, with the use of genetic markers across the
genome to predict individual drug responsiveness.
This new science, pharmacogenomics, aims to predict
both good and adverse clinical responses to individual
drugs.17 Since many drugs are metabolised by the cyto›
chrome P450 pathway, polymorphisms within the
P450 genes are good candidates for determining some
of these responses. P450 genotyping microarrays are
already available from Affymetrix and are probably
forerunners of arrays that will determine much larger
numbers of pharmacologically relevant genotypes.
Mutation detection and genotyping for specific
genes
Different types of microarray, used for re›sequencing of
known genes, allow massive stretches of an individual’s
DNA to be screened for mutations. Re›sequencing
arrays, based on a similar design, can already be used to
screen entire genes for pathogenic mutations such as
in the cancer susceptibility genes BRCA1 and p53.18
Gene specific arrays will also be of value for detecting
polymorphisms that induce specific diseases such as
factor V Leiden in deep vein thrombosis, apolipopro›
tein E4 in Alzheimer’s disease, and the recently identi›
fied susceptibility gene for Crohn’s disease, NOD2.14
Some arrays for this type of clinical use are already
under commercial development.
Microarrays and identification of new
disease genes
Three recent studies have combined the use of DNA
microarrays with genetic linkage analysis, leading to
identification of the disease genes under study. In the
first report microarrays were used to identify genes that
were differentially expressed between a rat strain with
insulin resistance and a normal, insulin sensitive
control strain.19 One of the genes identified in this
microarray study, Cd36 or fatty acid translocase,
mapped to a chromosomal location previously shown
to contain an insulin resistance gene.20 Defects in the
gene were then shown to result in glucose intolerance
and defective fatty acid metabolism, both in this rat
strain19 21 and in humans.22 In the other two studies,
microarray based expression profiles combined with
linkage analysis led to identification of ABC transport›
ers as disease genes in the autosomal recessive
conditions Tangier disease23 and sitosterolaemia.24
As yet, it is too soon to know if the combined
microarray and linkage approach will be more
generally applicable to identification of monogenic or
complex trait genes, but adoption of the approach in a
growing number of gene mapping laboratories will
answer this question in the next two to three years.
Progress towards clinical practice
Most microarray based tests are still in the develop›
ment stage, though substantial progress towards com›
mercialisation has occurred in some cases. The
increased clinical information provided by microarrays
should assure their entry into routine clinical practice
within the next three to five years, although the added
costs will have to be justified by the clinical benefit. Like
any new diagnostic tool, microarrays will have to be
rigorously appraised for sensitivity, specificity, and pre›
dictive value and, in some cases, licensing by regulatory
bodies. The high costs of microarray based tests will
inevitably limit the speed with which they are
introduced into clinical practice and initially restrict
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Fig 4 Kaplan›Meier plots of overall survival of patients with diffuse
large B cell lymphoma at low clinical risk (international prognostic
index score 0›2) who are grouped on the basis of their gene
expression profiles. Patients’ tumours in the upper plot show a
germinal centre›like gene expression profile while those in the lower
plot show an activated B cell›like profile. (Adapted with permission
from Alizadeh et al6)
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their use to teaching centres and specialised units.
However, given the huge potential gain in clinically rel›
evant information for individual patients and their dis›
eases, the technology is likely to reach most large
hospitals within the next 10 years.
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Educational resources
Relevant websites
• http://cmgm.stanford.edu/pbrown/array.html—The website of the Pat
Brown laboratory, where custom arrays were first built. Gives a simple
overview of the microarray process and a wealth of protocols for custom
array research
• www.gene›chips.com—A comprehensive information source for presently
available microarray platforms
Key reviews
Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays.
Nature 2000;405:827›36—An in depth description of how microarrays are
giving insights into gene function
The chipping forecast. Nature Genet 1999;21(suppl):1›60—A series of
reviews dealing comprehensively with microarray theory, manufacture, and
applications
Medical mishaps
Mistaken identity
The BMJ has recently focused on the
underreporting of adverse events and
near misses in the NHS. The clinical
review article entitled “Reporting and
preventing medical mishaps” (BMJ 2000;
320:759›63) stressed the importance of
reporting incidents, as near misses offer
numerous benefits over adverse events.
In the light of this and recent events we
would like to draw attention to the
following.
Working in a busy plastic surgery unit,
we have noticed that a variety of water,
saline, and lignocaine ampoules all look
virtually identical in terms of bottle
design and labelling (see figure ). Our
concerns about the potential for a
mistake being made were confirmed
recently during administration of a local
anaesthetic wrist block, when a vial
of water was mistaken for lignocaine.
Fortunately, in this case mistaking water for lignocaine had no
serious consequences other than requiring re›injection with local
anaesthetic. However, the potential consequences of an
accidental intravenous injection of lignocaine (such as while
preparing an intravenous infusion)
are obvious.
We have contacted the
manufacturers (B Braun), who are
aware of the similarity in labelling
and packages of these products.
They state that there is nothing
they can do about it and referred
us to the Medicines Control
Agency, which is ultimately
responsible for overseeing product
labelling.
When we contacted the agency it
said that it was aware of the
problem. Hopefully, in reporting
this near miss, we will have alerted
others to this potential danger. The
Medicines Control Agency may
even look further into its labelling
guidelines if others have had
similar experiences.
Charles Nduka specialist registrar in plastic surgery
Daniel Leff house officer in plastic surgery, Colchester General
Hospital, Essex
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